Benchling

The interesting thing about Benchling right now is not the notebook. Plenty of vendors sell an ELN. What the vendor has been building toward is agents that carry work forward between experiments, and the site now leads there — a request like "build me a foundry for antibody discovery" spawning agents for sequence generation, cloning, lab coordination, analysis, and next-round design. We'd want to see it run on our own data before believing the loop is as tight as the copy implies, but the direction is real and the packaged foundries give it something concrete to install. Pick Benchling when you're running genuine programs across multiple sites and the handoff between bench and computational teams is costing you cycles. The biology, chemistry, RNA/peptide, and antibody foundries mean you're not starting from a blank canvas, and the developer platform gives your informatics group room to extend things with APIs, SDKs, and shareable apps. Pass on it if you need a lightweight notebook. The platform rewards configuration, and somebody has to own that setup, validation, and training — an organization without that person will pay for capability it never touches. The closest alternative is stitching a standalone ELN to a separate LIMS and a homegrown data warehouse. That's defensible if both halves already work and your integration layer is solid. It gets ugly when you want the same entity — a plasmid, a cell line, a batch — referenced cleanly across a notebook entry, an instrument run, and a model input. That join is what you're buying here. Watch the real-world costs: validated environments add setup and compliance overhead, agent workflows need clean historical context to be worth much (the Regeneron example hinged on ingesting roughly 1,000 historical reports first),